Real-World Effectiveness of Nirmatrelvir-Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study.

ABSTRACT:

Background

Real-world data evaluating the effectiveness of nirmatrelvir-ritonavir across diverse age groups and vaccination statuses remain limited, particularly in East Asian populations. This study evaluates its effectiveness in reducing severe COVID-19 outcomes using a large, comprehensive nationwide healthcare database and to provide new evidence.

Method

This retrospective observational cohort study involved outpatient COVID-19 patients diagnosed between 1 January 2022, and 1 December 2022, within Taiwan's National Health Insurance Research Database. Patients who received nirmatrelvir-ritonavir were compared with untreated patients. Primary outcomes include COVID-19-related hospitalization, ICU admission, invasive ventilatory support, death, and the composite outcome of

SUBMITTER: Kuo RN 

PROVIDER: S-EPMC12451265 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature